Pharming Group (NASDAQ:PHAR) Shares Up 3.9% - Here's Why

Pharming Group (NASDAQ:PHAR - Get Free Report) shares traded up 3.9% during mid-day trading on Thursday . The stock traded as high as $11.56 and last traded at $11.97. 796 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 6,236 shares. The stock had previously closed at $11.52.

Analyst Ratings Changes

A number of analysts have recently weighed in on PHAR shares. HC Wainwright reiterated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 20th. Oppenheimer upped their target price on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research report on Friday, March 14th.

Pharming Group Trading Up 3.9%

The business has a 50-day moving average price of $9.57 and a two-hundred day moving average price of $9.13. The stock has a market capitalization of $813.99 million, a P/E ratio of -46.02 and a beta of 0.02. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The business had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million. On average, analysts expect that Pharming Group will post -0.2 EPS for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.